Status:
COMPLETED
In Vitro Activity of Ceftolozane-tazobactam Against Contemporary Nosocomial Gram "-" Pathogens Isolated in Russia
Lead Sponsor:
The Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC)
Conditions:
Nosocomial Infection
Eligibility:
All Genders
Up to 90 years
Brief Summary
Infections caused by resistant gram-negative bacteria are becoming increasingly prevalent and now constitute a serious threat to public health worldwide because they are difficult to treat and are ass...
Detailed Description
Infections caused by resistant gram-negative bacteria are becoming increasingly prevalent and now constitute a serious threat to public health worldwide because they are difficult to treat and are ass...
Eligibility Criteria
Inclusion
- consecutive, non-duplicate (one per patient/episode of infection), gram-negative clinical isolates collected from patients with intra-abdominal, urinary tract, lower respiratory tract, and bloodstream nosocomial infections
Exclusion
- Non-Enterobacteriaceae isolates after reidentification
Key Trial Info
Start Date :
February 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2020
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT04679610
Start Date
February 1 2017
End Date
December 1 2020
Last Update
December 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy
Smolensk, Russia, 214019